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Trajectories of cardiometabolic risk factors before diagnosis 
of three subtypes of type 2 diabetes: a post-hoc analysis of 
the longitudinal Whitehall II cohort study
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Summary
Background Most clinicians acknowledge that type 2 diabetes is multifactorial and has heterogeneous characteristics, 
but neither prevention nor treatment is systematically stratiﬁ ed. To address the heterogeneity of the disease, we 
examined whether patients diagnosed on the basis of fasting glucose concentrations, those diagnosed on the basis of 
2 h concentrations, and those diagnosed on the basis of both criteria diﬀ ered in terms of pathogenesis or 
cardiovascular risks. 
Methods Retrospectively, we analysed trajectories of cardiometabolic risk factors and 10 year cardiovascular risks in the 
prospective Whitehall II study cohort by use of multilevel longitudinal modelling. Participants were diagnosed by 75 g 
oral glucose-tolerance tests. We classiﬁ ed those diagnosed with type 2 diabetes into three subgroups: diagnosed on the 
basis of fasting glucose concentrations, diagnosed on the basis of 2 h glucose concentrations, and diagnosed on the basis 
of both concentrations. We also developed a classiﬁ cation tree for identiﬁ cation of individuals who are likely to have high 
fasting and 2 h glucose concentrations, but for whom only fasting concentrations are available. 
Results Median follow-up was 14·2 years with 15 826 person-examinations (1991–2009). Of 10 308 individuals, 6843 
were included and 6569 remained diabetes free. 274 cases of type 2 diabetes were identiﬁ ed: 55 had high fasting 
glucose concentrations only, 148 had high 2 h concentrations only, and 71 had high fasting and 2 h concentrations. At 
diagnosis, participants with high fasting and 2 h glucose concentrations had higher mean body-mass indices 
(30·9 kg/m2 [SD 5·7]) than did those with high fasting concentrations (28·4 kg/m2 [4·4]; p=0·0009) or 2 h 
concentrations (27·9 kg/m2 [4·9]; <0·0001). Mean glycated haemoglobin A1c concentrations were also higher in the 
fasting and 2 h subgroup (7·4% [1·6]) than in the fasting (5·9% [0·5]; <0·0001) or 2 h (5·9% [0·6]; <0·0001) sugroups. 
Additionally, the fasting and 2 h subgroup had a higher proportion of individuals with moderate or high risk of 
cardiovascular disease than did the fasting subgroup (p=0·02). A classic pattern of β-cell decompensation before 
diagnosis was noted only in the fasting and 2 h subgroup. Additionally, glucose concentrations and insulin resistance 
accelerated more substantially before diagnosis in the fasting and 2 h subgroup than in the fasting subgroup or the 
2 h subgroup. 
Interpretation Patients with type 2 diabetes diagnosed on the basis of increased fasting glucose concentrations or 2 h 
glucose concentrations, or both, have distinct cardiometabolic risk development before diagnosis. 
Funding UK Medical Research Council, UK Economic and Social Research Council, British Heart Foundation, UK 
Health and Safety Executive, UK Department of Health, US National Heart Lung and Blood Institute, US National 
Institute on Aging, US Agency for Health Care Policy Research, and John D and Catherine T MacArthur Foundation. 
Introduction 
Type 2 diabetes is deﬁ ned as a single disease entity 
irrespective of the way in which it is diagnosed. Even 
though most clinicians recognise that the disease is 
multifactorial and has heterogeneous characteristics, 
stratiﬁ cation of prevention or treatment is not done 
systematically.
As type 2 diabetes develops, the blood glucose rises from 
normoglycaemia to a slightly increased concentration (ie, 
prediabetic state) and ﬁ nally to a hyperglycaemic state that 
exceeds the diagnostic criteria for the illness. Previous 
longitudinal analyses1 from the Whitehall II study have 
shown that fasting and 2 h postload glucose concentrations 
increase at diﬀ erent timepoints in the years preceding 
diagnosis of type 2 diabetes, suggesting possible 
diﬀ erences in disease development. Individuals with 
prediabetes in whom only fasting plasma glucose 
concentrations are raised are phenotypically diﬀ erent 
from those with increased 2 h glucose concentrations 
only.2–4 Individuals in whom both fasting and 2 h glucose 
concentrations are raised have a worse risk proﬁ le3,4 and a 
higher risk of progression to type 2 diabetes5 than do those 
with isolated fasting or 2 h hyperglycaemia. The major 
pathophysiological drivers in the diﬀ erent prediabetic 
states probably continue to operate when fasting or 2 h 
glucose concentrations further rise into the diabetic range, 
implying that stratiﬁ ed prevention and possibly stratiﬁ ed 
treatment might be beneﬁ cial. In this longitudinal cohort 
study, we established 18 year trajectories of traditional 
cardio metabolic risk factors preceding diagnosis of type 2 
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diabetes based on fasting glucose or 2 h glucose 
concentrations, or both. We also developed a model to 
identify the individuals who are likely to have high fasting 
and 2 h glucose concentrations, but for whom only fasting 
concentrations are available. 
Methods
Study design and participants 
Whitehall II was a longitudinal study of a cohort of non-
industrial UK civil servants and has been previously 
described in detail.6 Its original aim was to investigate the 
importance of stress and social class for cardiovascular 
health. 10 308 participants (6896 [66·9%] of whom were 
male) who worked in the London oﬃ  ces of 20 departments 
and were aged 35–55 years were recruited between 
August, 1985, and April, 1988 (phase 1), and followed up in 
eight subsequent phases roughly 2·5 years apart. A 
questionnaire was administered in all phases, and every 
second phase (ie, phases 1, 3, 5, 7, and 9) additionally 
included a clinical health examination. The numbers of 
participants in these subsequent clinical phases, which 
were deﬁ ned as the numbers who either returned a 
questionnaire or attended a clinical examination, were 
6057 men and 2758 women in phase 3 (1991–93), 5473 men 
and 2397 women in phase 5 (1997–99), 4893 men and 
2074 women in phase 7 (2002–04), and 4759 men and 2002 
women in phase 9 (2007–09). The Whitehall II study was 
reviewed and approved by the University College London 
Diabetes based on 
fasting glucose (n=55)
Diabetes based on 2 h 
glucose (n=148)
Diabetes based on 
fasting and 2 glucose 
(n=71)
Participants without 
diabetes (n=6569)
Men 44 (80·0%) 107 (72·3%) 57 (80·3%) 4618 (70·3%)
Age (years) 60·0 (6·9) 63·0 (6·6)* 60·8 (6·0) 60·4 (7·9)†
White ethnic origin 43 (78·2%) 125 (84·5%) 53 (74·6%) 6063 (92·3%)‡
Current smoker 2 (3·6%) 11 (7·4%) 10 (14·1%) 650 (9·9%)
Family history of diabetes mellitus 13 (23·6%) 33 (22·3%) 17 (23·9%) 617 (9·4%)‡
10 year cardiovascular disease risk ≥15% 22 (40·0%) 70 (47·3%) 43 (60·6%)* 434 (6·6%)‡
Antihypertensive treatment 19 (34·5%) 58 (39·2%) 22 (31·0%) 1478 (22·5%)†
Lipid-lowering treatment 11 (20·0%) 34 (23·0%) 11 (15·5%) 1031 (15·7%)†
Fasting plasma glucose (mmol/L) 7·3 (0·5) 5·8 (0·7)* 9·1 (2·7)§ 5·2 (0·5)‡
2 h plasma glucose (mmol/L) 8·2 (2·0) 12·2 (1·0)* 15·5 (4·0)§ 6·0 (1·6)‡
HbA1c
% 5·9 (0·5) 5·9 (0·6) 7·4 (1·6)§ 5·5 (0·4)‡
mmol/mol 41 (5·7) 41 (6·5) 57 (17·7) § 37 (4·6)‡
Body-mass index (kg/m2) 28·4 (4·4) 27·9 (4·9) 30·9 (5·7)§ 26·2 (4·1)‡
Waist circumference (cm) 100·0 (12·5) 97·5 (12·1) 104·4 (11·4)† 91·8 (12·2)‡
Hip circumference (cm) 102·8 (8·9) 101·6 (9·0) 105·2 (11·3)† 99·8 (7·9)‡
Waist–hip ratio 0·97 (0·07) 0·96 (0·07) 1·00 (0·07)† 0·92 (0·08)‡
Height (m) 172·2 (9·9) 168·9 (9·3)* 171·4 (8·0) 171·4 (9·2)†
Total cholesterol (mmol/L) 5·8 (1·2) 5·7 (1·1) 5·9 (1·0) 5·7 (1·2)
HDL cholesterol (mmol/L) 1·4 (0·3) 1·5 (0·4) 1·2 (0·3)† 1·6 (0·4)¶
LDL cholesterol (mmol/L) 3·7 (1·2) 3·5 (1·0) 3·7 (0·9) 3·6 (1·1)
Triglycerides (mmol/L) 1·6 (0·8) 1·5 (0·8) 2·0 (1·0)§ 1·3 (0·8)‡
Adiponectin (μg/mL)|| 6·5 (6·4–11·3) 6·4 (5·1–8·8) 4·9 (3·3–8·7) 8·7 (6·3–13·2)**
Systolic blood pressure (mm Hg) 127·9 (17·5) 132·6 (18·4) 138·3 (17·9)§ 124·0 (15·6)**
Diastolic blood pressure (mm Hg) 75·3 (11·1) 77·6 (12·2) 83·1 (12·9)§ 74·2 (10·8)**
Fasting insulin (pmol/L) 14·7 (8·6–22·1) 10·6 (6·7–16·3)* 17·0 (10·5–22·1)† 6·6 (4·4–9·9)‡
2 h insulin (pmol/L) 57·5 (35·2–93·7) 88·7 (60·1–131·6) 50·4 (35·6–90·8)† 37·9 (23·2–62·9)‡
HOMA-insulin resistance 4·7 (3·0–6·8) 2·9 (1·8–4·6)* 6·2 (3·9–8·5)§ 1·6 (1·1–2·4)‡
HOMA-β-cell function 77·1 (48·3–105·0) 95·7 (66·5–151·1)* 66·3 (37·0–100·0)† 86·3 (60·3–124·6)¶
Insulin sensitivity index (mg l2/mmol mU min) 47·8 (36·9–65·6) 33·9 (28·3–41·4)* 31·8 (25·5–44·0)* 91·4 (61·7–150)‡
Data are n (%), mean (SD), or median (IQR). HOMA=homoeostasis model of assessment. To test diﬀ erences in characteristics between subgroups, the χ² test was used for 
categorical variables, t test for normal continuous data, and Mann-Whitney U test for non-normal continuous data. Two-sided 5% level of signiﬁ cance adjusted for multiple 
testing with Benjamini et al’s method.13 *Signiﬁ cantly diﬀ erent from fasting subgroup. †Signiﬁ cantly diﬀ erent from 2 h subgroup. ‡Signiﬁ cantly diﬀ erent from fasting, 2 h, 
and fasting and 2 h subgroups. §Signicantly diﬀ erent from fasting subgroup and 2 h subgroup. ¶Signiﬁ cantly diﬀ erent from fasting subgroup and fasting and 2 h subgroup. 
||n=24 in the fasting subgroup, n=70 in the 2 h subgroup, n=36 in the fasting and 2 h subgroup, and n=2336 in the diabetes-free group. **Signiﬁ cantly diﬀ erent from 2 h 
subgroup and fasting and 2 h subgroup.
Table: Characteristics of patients with type 2 diabetes diagnosed on the basis of fasting glucose concentrations or 2 h concentrations, or both, at time of 
diagnosis, and of those without diabetes at last clinical examination
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Ethics Committee (85/0938), and written informed 
consent was obtained from each participant at each phase. 
The study was done according to the principles of the 
Helsinki Declaration.
Procedures 
We used phase 3—ie, when the oral glucose tolerance 
test (OGTT) was ﬁ rst done—as the baseline for our 
analysis, and ﬁ nal follow-up was the phase 9 
examination. We excluded 1032 (10·0%) participants 
who were lost to follow-up before phase 3, 153 (1·5%) 
participants with prevalent diabetes before phase 3, and 
1759 (17·1%) participants who fasted for less than 8 h 
before the clinical examination in all study phases. 
When fasting duration was less than 8 h in one phase, 
the participant was excluded from that phase only. 795 of 
the remaining 7364 (10·8%) participants developed 
type 2 diabetes during the study. However, because 
diagnosis with a full and valid OGTT was necessary,7 we 
further excluded 358 (4·9%) patients whose type 2 
diabetes was diagnosed by a doctor outside the study and 
163 (2·3%) participants in whom the disorder was 
diagnosed by screening, but for whom data for both a 
valid fasting and 2 h glucose measurement were not 
available. Thus, our ﬁ nal sample was 6843 participants 
(66·4% of the original sample); median follow-up was 
14·2 years (IQR 8·7–16·2), 15 826 person-examinations 
were done, and 274 cases of  type 2 diabetes were 
diagnosed by screen detection by phase 9. We classiﬁ ed 
these 274 cases into three subgroups—namely, cases 
diagnosed on the basis of fasting glucose only (ie, fasting 
glucose ≥7·0 mmol/L, 2 h glucose <11·1 mmol/L), those 
diagnosed on the basis of 2 h glucose only (ie, fasting 
glucose <7·0 mmol/L, 2 h glucose ≥11·1 mmol/L), and 
those diagnosed on the basis of both criteria (ie, fasting 
glucose ≥7·0 mmol/L, 2 h glucose ≥11·1 mmol/L). A 
ﬂ ow diagram of the number of participants included at 
each phase is shown in the appendix.
Measurements 
In phases 3, 5, 7, and 9 of Whitehall II, standard 2 h 75 g 
OGTTs were done in the morning after overnight fasting 
(≥8 h, estimated by the diﬀ erence between self-reported 
time of most recent meal and the OGTT), or in the 
afternoon after no more than a light fat-free breakfast 
eaten before 0800 h (≥5 h of fasting). 
Anthropometry was done and blood pressure 
measured according to standard protocols.6 Data for 
ethnic origin, smoking status, and family history of 
diabetes (types 1 and 2) were gathered via a questionnaire. 
During all phases, blood samples were handled 
according to standardised procedures. Blood glucose 
was measured by the glucose oxidase method;1 serum 
insulin by in-house radioimmunoassays;8 and serum 
triglycerides, total cholesterol, and HDL cholesterol 
concentrations by automated enzymatic colorimetric 
methods. LDL cholesterol was calculated with the 
Friedewald formula, and serum adiponectin 
concentrations measured in 2466 (36·0%) participants 
with the Quantikine ELISA kit (R&D Systems, 
Wiesbaden, Germany).9
Statistical analysis 
We used the homoeostasis model assessment (HOMA) 
to estimate insulin resistance and β-cell function,10 the 
insulin sensitivity index to estimate whole-body insulin 
sensitivity,11 and the Framingham cardiovascular disease 
risk score to calculate absolute 10 year risk of developing 
general cardiovascular disease.12 We classiﬁ ed a risk score 
of 15% or greater as a moderate or high risk of 
cardiovascular disease.
The observation period for retrospective trajectories 
started at the date of diagnosis by OGTT for patients 
who developed type 2 diabetes, and at the last screening 
or questionnaire phase for those who did not develop the 
disorder (year 0). Trajectories of the following outcomes 
were followed back in time to the ﬁ rst clinical exam-
ination: fasting and 2 h plasma glucose concentrations; 
fasting and 2 h serum insulin concentrations; HOMA-β-
cell function, HOMA-insulin resistance, and insulin 
sensitivity index; body-mass index and waist–hip ratio; 
systolic and diastolic blood pressure; total, HDL, and 
Figure 1: Trajectories of fasting plasma glucose (A), 2 h plasma glucose (B), fasting serum insulin (C), and 2 h 
serum insulin (D) concentrations for a hypothetical, white, 60-year-old man (in year 0)  from 18 years before 
diagnosis of type 2 diabetes or last clinical examination 
Time 0=diagnosis or last clinical examination. Solid lines are estimated trajectories and dashed lines are 95% CIs. 
Black bars show data distribution during follow-up.
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LDL cholesterol concentrations; triglyceride concen-
trations; adiponectin concentrations; and the 
Framingham cardiovascular disease risk score. Before 
analysis, we log-transformed outcomes that did not 
follow a normal distribution (fasting and 2 h serum 
insulin concentrations, adiponectin concentrations, 
HOMA-β-cell function, HOMA-insulin resistance, and 
insulin sensitivity index). 
We used mixed-eﬀ ects models to account for the 
correlation of repeated measurements within participants. 
Time dependence was allowed to vary across the 
subgroups, and quadratic and cubic terms for time were 
included in the three subgroups when signiﬁ cant (two-
sided 5% signiﬁ cance level). For individuals who did not 
develop diabetes, year 0 was merely a timepoint in a 
normal life course, and thus we ﬁ tted the trajectories by 
linear models. We adjusted all analyses for age, sex, 
ethnic origin, and study phase. Pairwise diﬀ erences in 
growth curves between the three subgroups were tested 
with the F test by comparing the curve of contrasts by 
diabetes subgroups with a straight line with zero slope 
that passes through the origin (two-sided 5% signiﬁ cance 
level). Accordingly, provided p values relate to curve 
diﬀ erences in slope or intercept, or both. We did statistical 
analyses in R (version 9.15.0) and SAS (version 9.2).
To acknowledge that OGTTs are rarely done in clinical 
practice, we developed a classiﬁ cation tree for identi-
ﬁ cation of individuals with type 2 diabetes who are likely 
to have the fasting and 2 h phenotype but for whom 2 h 
glucose concentrations are not available. We derived a 
classiﬁ cation tree for type 2 diabetes by both criteria 
based on a two-step approach—an initial screening of 
the explanatory variables listed in the table (not including 
2 h glucose and drugs) by random forests analysis with 
fasting and 2 h concentrations as the outcome, and 
derivation of a classiﬁ cation tree based on the ﬁ ve 
highest ranking variables (appendix).
Role of the funding source 
The sponsors of the study did not have roles in study 
design; data collection, analysis, and interpretation; or 
writing of the report. All authors accept full responsibility 
for the study, had full access to all the data, and take 
responsibility for the integrity of the data and the 
accuracy of the analysis. The corresponding author had 
the ﬁ nal responsibility to submit for publication.
Results 
The Table shows characteristics of participants at the date 
of diagnosis for the three subgroups of type 2 diabetes or 
the last clinical examination for those without type 2 
diabetes. Of the 274 people who developed type 2 diabetes, 
55 (20·1%) had high fasting glucose concentrations, 
148 (54·0%) had high 2 h concentrations, and 71 (25·9%) 
had high fasting and 2 h concentrations. At diagnosis 
(year 0), individuals with 2 h hyperglycaemia were older 
and had lower fasting insulin concentrations, HOMA-
insulin resistance, and insulin sensitivity (as measured by 
the insulin senstivity index), but higher 2 h insulin 
concentrations and β-cell function than did those with 
fasting hyperglycaemia. Individuals with high fasting and 
2 h glucose concentrations were generally more obese, had 
lower HDL cholesterol concentrations and β-cell function, 
and higher triglyceride and glycated haemoglobin A1c 
(HbA1c) concentrations and blood pressure than did the 
subgroups with high fasting concentrations or high 2 h 
concentrations only. Furthermore, the proportion of 
individuals with moderate or high cardiovascular risk was 
higher in the fasting and 2 h subgroup than in the fasting 
subgroup (table; p=0·02). For most variables, less than 5% 
of data were missing. However, for insulin resistance, 
β-cell function, insulin sensitivity index, waist–hip ratio, 
cardiovascular risk, and HDL and LDL cholesterol 
concentrations, 5–10% of data were missing.
Trajectories of fasting and 2 h glucose diﬀ ered between 
the subgroups in accordance with the criteria by which 
type 2 diabetes was diagnosed (ﬁ gure 1A, 1B; p<0·0001 
for all comparisons). However, the curves did not diverge 
until roughly 6 years before diagnosis, when  both fasting 
and 2 h glucose concentrations rose steeply in the fasting 
and 2 h subgroup. Fasting insulin concentrations rose 
slightly but steadily in the three diabetes subgroups from 
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Figure 2: Trajectories of HOMA-insulin resistance (A), HOMA-β-cell function (B), insulin sensitivity index (C), 
and serum adiponectin concentrations (D) for a hypothetical, white, 60-year-old man (in year 0) from 
18 years before diagnosis of type 2 diabetes or last clinical examination
Time 0=diagnosis or last clinical examination. Solid lines are estimated trajectories and dashed lines are 95% CIs. 
Black bars show data distribution during follow-up. Adiponectin concentrations are based on a subset of data. 
HOMA=homoeostasis model of assessment.
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15 years before diagnosis compared with those in 
participants without type 2 diabetes (ﬁ gure 1C); this 
increase was less pronounced in the 2 h subgroup 
(p=0·037 compared with fasting subgroup and 0·0001 
compared with fasting and 2 h subgroup). Heterogeneity 
between the subgroups was greater for the trajectories for 
2 h insulin concentrations (ﬁ gure 1D, p=0·0033 for 
fasting subgroup vs 2 h subgroup, 0·0326 for fasting 
subgroup vs fasting and 2 h subgroup, and <0·0001 for 
2 h subgroup vs fasting and 2 h subgroup). In the fasting 
and 2 h subgroup, 2 h insulin concentrations peaked 
around 5 years before diagnosis and then started to fall, 
whereas 2 h insulin concentrations increased linearly in 
patients who developed type 2 diabetes according to 
fasting criteria or 2 h criteria, but at diﬀ erent rates 
(ﬁ gure 1D; p=0·003 for fasting subgroup vs 2 h subgroup).
Trajectories of insulin resistance broadly resembled 
those of fasting glucose concentrations and diﬀ ered 
signiﬁ cantly between all three subgroups (ﬁ gure 2A; 
p<0·0001 for fasting subgroup vs 2 h subgroup and for 
2 h subgroup vs fasting and 2 h subgroup, 0·0002 for 
fasting subgroup vs fasting and 2 h subgroup). Trajectories 
of β-cell function also diﬀ ered signiﬁ cantly between the 
three subgroups (ﬁ gure 2B; p=0·0002 for fasting 
subgroup vs 2 h subgroup, 0·0140 for fasting subgroup vs 
fasting and 2 h subgroup, and <0·0001 for 2 h subgroup 
vs fasting and 2 h subgroup). In the fasting and 2 h 
subgroup, percentage β-cell function increased until 
roughly 8–10 years before diagnosis and fell progressively 
thereafter (ﬁ gure 2B). By contrast, patients in the 2 h 
subgroup had moderately stable values throughout 
follow-up (ﬁ gure 2B). Individuals in the fasting subgroup 
had signiﬁ cantly lower HOMA-β-cell function from 
18 years before diagnosis until diagnosis than did those 
who did not have type 2 diabetes (p<0·0001). Scores on 
the insulin sensitivity index were lower in the three 
subgroups of type 2 diabetes before and at diagnosis than 
they were in the participants who did not develop type 2 
diabetes (p<0·0001 for all comparisons); scores decreased 
slightly faster in the 2 h subgroup and fasting and 2 h 
subgroup than in the fasting subgroup (ﬁ gure 2C, 
p=0·0006 for fasting subgroup vs 2 h subgroup, and 
0·0093 for fasting subgroup vs fasting and 2 h subgroup). 
Individuals diagnosed by fasting and 2 h concentrations 
had lower serum adiponectin concentrations before 
diagnosis than did those diagnosed by either fasting or 2 h 
concentrations (ﬁ gure 2D, p=0·0203 for fasting subgroup 
vs fasting and 2 h subgroup and 0·0504 for 2 h subgroup 
vs fasting and 2 h subgroup).
Body-mass indices and waist–hip ratios increased 
linearly with time in the three subgroups (ﬁ gure 3A, 3B). 
However, obesity was more common in patients diagnosed 
by  fasting and 2 h glucose concentrations than in those 
diagnosed by either fasting or 2 h concentrations 
(ﬁ gure 3A, B; p=0·0029 for fasting subgroup vs fasting and 
2 h subgroup and <0·0001 for 2 h subgroup vs fasting and 
2 h subgroup). 
The increase in both diastolic (data not shown) and 
systolic blood pressure with time was steepest in the 
sub group diagnosed on the basis of fasting and 2 h 
glucose concentrations (ﬁ gure 3C; p=0·0009 for fasting 
subgroup vs fasting and 2 h subgroup and 0·0150 for 2 h 
subgroup vs fasting and 2 h subgroup). Trajectories of 
estimated risk of cardiovascular disease diﬀ ered 
signiﬁ cantly between the three subgroups (ﬁ gure 3D; 
p=0·0024 for fasting subgroup vs 2 h subgroup and 
<0·0001 for fasting subgroup vs fasting and 2 h subgroup 
and 2 h subgroup vs fasting and 2 h subgroup); risk was 
highest in the fasting and 2 h subgroup (p<0·0001).
The trajectories of total and LDL cholesterol 
concentrations did not diﬀ er signiﬁ cantly between 
subgroups (ﬁ gure 4A, 4B; p≥0·334 for all pairwise 
comparisons). However, HDL cholesterol concentrations 
decreased signiﬁ cantly more in the subgroup diagnosed 
on the basis of fasting and 2 h glucose concentrations 
than in that diagnosed on the basis of 2 h concentrations 
(ﬁ gure 4C; p=0·0005), and patients diagnosed on the 
basis of both criteria had higher increases in 
concentrations of plasma triglycerides than did those 
diagnosed by either fasting or 2 h concentrations 
(ﬁ gure 4D, p=0·0056 for fasting subgroup vs fasting and 
Figure 3: Trajectories of body-mass index (A), waist–hip ratio (B), systolic blood pressure (C), and 10 year 
absolute risk of cardiovascular disease (Framingham) (D) for a hypothetical, white, 60-year-old man 
(in year 0) from 18 years before diagnosis of type 2 diabetes or last clinical examination
Time 0=diagnosis or last clinical examination. Solid lines are estimated trajectories and dashed lines are 95% CIs. 
Black bars show data distribution during follow-up.
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2 h subgroup and 0·0004 for 2 h subgroup vs fasting and 
2 h subgroup). 
 In our study, 71 of the 126 (56·3%) individuals with 
fasting glucose concentrations in the diabetic range also 
had 2 h concentrations in the diabetic range; the 
126 patients were used to derive the classiﬁ cation tree. 
The random forest analysis showed that the ﬁ ve highest 
ranking explanatory variables that discriminate between 
people diagnosed on the basis of fasting glucose 
concentrations only and those diagnosed on the basis of 
fasting and 2 h concentrations were fasting plasma 
glucose concentrations, HbA1c concentrations, diastolic 
blood pressure, systolic blood pressure, and HOMA-
insulin resistance. The resulting classiﬁ cation tree was 
based on these variables, but only fasting glucose and 
HbA1c concentrations were signiﬁ cant in the model. 55 of 
65 (85%) individuals with fasting plasma glucose 
concentrations greater than 7·2 mmol/L and HbA1c 
greater than 6·3% (45 mmol/mol) had the fasting and 
2 h phenotype (ﬁ gure 5, appendix).
Discussion
We hypothesised that type 2 diabetes is not a single disease 
entity, but rather a heterogeneous disease with diﬀ erent 
underlying mechanisms preceding diagnosis in diﬀ erent 
groups of individuals. We did a simple stratiﬁ cation based 
on the common diagnostic glucose criteria of the 
Whitehall II cohort and showed that underlying 
pathogenesis diﬀ ered as much as 18 years before diagnosis 
between patients with type 2 diabetes diagnosed on the 
basis of increased fasting glucose concentrations, those 
diagnosed on the basis of 2 h concentrations, and those 
diagnosed on the basis of both criteria (panel). 
 In the fasting and 2 h subgroup, HbA1c concentrations 
surpassed the diagnostic threshold for type 2 diabetes 
(6·5%) at time of diagnosis, whereas, in the fasting 
subgroup and the 2 h subgroup, mean HbA1c was less 
than the cutoﬀ   (6·0%) for high-risk type 2 diabetes.14 
Despite moderately normal HbA1c concentrations, both 
the fasting subgroup and the 2 h subgroup had 
signiﬁ cantly increased estimated 10 year risk of 
cardiovascular disease compared with people without 
type 2 diabetes, suggesting that HbA1c might not be a 
good marker of cardiovascular risk in all patients with 
type 2 diabetes.
Over the past two decades, the results of several 
studies2,15,16 have suggested that fasting and post-OGTT 
hyperglycaemia represent phenotypes with distinct 
natural histories, a notion supported by our ﬁ ndings. We 
noted a long-standing reduction in basal β-cell function 
and a progressive increase in insulin resistance in 
patients developing type 2 diabetes diagnosed on the 
basis of fasting glucose concentrations. Thus, the 
increased fasting insulin concentration before onset 
(ﬁ gure 1C) shows inadequate compensation for the 
increased insulin resistance.17 Because of the low β-cell 
function in this subgroup before and at diagnosis, 
individuals with fasting hyperglycaemia might beneﬁ t 
from early prevention strategies focusing on prevention 
of further loss of β-cell function rather than strategies 
targeting peripheral insulin sensitivity. This line of 
thinking is supported by observational and interventional 
Figure 4: Trajectories for total cholesterol (A), LDL cholesterol (B), HDL cholesterol (C), and triglyceride (D) 
concentrations for a hypothetical, white, 60-year-old man (in year 0) from 18 years before diagnosis of type 
2 diabetes or last clinical examination
Time 0=diagnosis or last clinical examination. Solid lines are estimated trajectories and dashed lines are 95% CIs. 
Black bars show data distribution during follow-up.
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Figure 5: Classiﬁ cation tree for identiﬁ cation of patients with fasting and 2 h 
hyperglycaemia without results from an oral glucose tolerance test 
Sensitivity=78% (95% CI 68–87); speciﬁ city=82% (71–91); positive predictive 
value=85% (appendix). HbA1c=glycated haemoglobin A1c.
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studies18,19 showing that physical activity, which mainly 
improves peripheral insulin sensitivity, has little eﬀ ect 
on progression to type 2 diabetes in individuals with 
isolated impaired fasting glucose concentrations (ie, 2 h 
concentrations are normal), but is protective in those 
with impaired glucose tolerance (who have prediabetic 
2 h glucose concentrations). By contrast, metformin, 
which mainly works by improving hepatic insulin 
sensitivity, seemed to be more eﬀ ective in people with 
high fasting glucose concentrations than in those with 
low fasting concentrations in the Diabetes Prevention 
Program.20 
To further disentangle the underlying causes of 
diﬀ erences in patterns of insulin resistance and β-cell 
function between subgroups of type 2 diabetes, a detailed 
examination of the contributing genetic and non-genetic 
factors is needed. The eﬀ ects of genes associated with 2 h 
glucose concentrations increase with age, whereas those 
of genes associated with fasting glucose concentrations 
are more stable with time,21 suggesting diﬀ erent genetic 
eﬀ ects in the diﬀ erent disease subgroups of our study. 
In patients who developed type 2 diabetes diagnosed 
on the basis of 2 h concentrations, 2 h insulin 
concentrations increased exponentially, whole-body 
insulin sensitivity fell, and fasting β-cell function was 
stable and almost normal. However, the increase in 
insulin secretion 2 h after the OGTT was not suﬃ  cient to 
maintain 2 h plasma glucose concentrations within the 
non-diabetic range, suggesting peripheral insulin 
resistance with insuﬃ  cient β-cell compensation.17,22,23 In 
general, type 2 diabetes diagnosed on the basis of 2 h 
glucose concentrations accounts for 30–50% of all cases.24 
However, in clinical practice OGTTs are seldom done 
and thus illness often remains undiagnosed and 
untreated in individuals with the 2 h phenotype. Because 
2 h glucose concentrations are more closely related to 
cardiovascular risk than are fasting glucose 
concentrations,25,26 we expected that progression of blood 
pressure, concentrations of plasma lipids and 
adiponectin, and cardiovascular risk would be worse in 
patients in the 2 h subgroup than in those in the fasting 
subgroup. However, although the 2 h subgroup had a 
slightly higher estimated cardiovascular risk at time of 
diagnosis than did the fasting subgroup, they had a 
slower worsening of plasma lipids. A previous study27 
showed that a rapid rise in triglyceride concentrations 
precedes type 2 diabetes diagnosed on the basis of fasting 
glucose concentrations, but we did not conﬁ rm this 
ﬁ nding. Rather, patients with increased fasting and 2 h 
glucose concentrations had higher triglyceride and lower 
adiponectin concentrations than did those in the other 
subgroups, independent of lipid-lowering treatment 
(data not shown). 
The pattern of insulin secretion in the fasting and 2 h 
subgroup (increased β-cell function 10–15 years before 
diagnosis and subsequent decline thereafter)  was not 
noted in the fasting subgroup or the 2 h subgroup, 
showing that the common notion that early β-cell 
compensation followed by a progressive loss of β-cell 
function is typical of the development of type 2 diabetes1,28 
seems only to apply to the fasting and 2 h subgroup, 
constituting roughly 25% of all screen-detected patients. 
This ﬁ nding also supports the idea that increases of both 
fasting and 2 h glucose concentrations are not merely a 
mixture of the underlying conditions of isolated fasting or 
2 h hyperglycaemia, but rather a distinct disease entity.3 
To identify patients with progressively declining β-cell 
function, accelerated increase of glucose concentrations, 
and high cardiovascular risk, knowledge of the patients’ 
subtype can be useful. Because OGTTs are not done on a 
regular basis in primary care, other methods to identify 
individuals in the high-risk subgroup might be needed. 
We noted that 85% of individuals with a fasting glucose 
concentration greater than 7·2 mmol/L and HbA1c 
concentration greater than 6·3% (45 mmol/mol) also 
had 2 h glucose concentrations in the diabetic range. 
Thus, the combination of fasting glucose and HbA1c 
concentrations might be useful to identify high-risk 
individuals who have accelerated β-cell dysfunction and 
are especially likely to beneﬁ t from early glucose-
lowering treatment and intensiﬁ ed cardiovascular 
disease prevention. However, this ﬁ nding needs to be 
conﬁ rmed in independent datasets.
Panel: Research in context
Systematic review
We searched PubMed for studies of adults (≥19 years) 
published in English before Dec 18, 2012, with the terms 
“type 2 diabetes” and “heterogeneity” in the title or abstract. 
Of the 157 references returned, 72 were focused on genetics 
of type 2 diabetes. The remaining 85 publications included 
34 reviews or meta-analyses, eight clinical trials, and 
43 observational studies. 35 publications concerned the 
pathogenesis of type 2 diabetes. We searched the reference 
lists in these publications and selected citations that we 
judged relevant. We noted no previous studies investigating 
metabolic features preceding development of subtypes of 
type 2 diabetes diagnosed by fasting versus 2 h glucose 
concentrations. 
Interpretation
Individuals with prediabetes diﬀ er in their natural history and 
underlying pathogenesis dependent on whether they have 
increased fasting glucose concentrations or increased 2 h 
glucose concentrations, or both. We showed that such 
diﬀ erences are also present in individuals with incident type 2 
diabetes. To distinguish between patients with isolated fasting 
hyperglycaemia and those with fasting and 2 h hyperglycaemia 
is important, because these subgroups have distinct natural 
histories of β-cell dysfunction and cardiovascular risk. More 
research is needed to understand how the speciﬁ c mechanisms 
that trigger type 2 diabetes can be used to optimise treatment 
and prevention of complications.
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Our study has some limitations. Estimates of insulin 
sensitivity and β-cell function were based on HOMA 
and the insulin sensitivity index, which are calculated 
from fasting and 2 h glucose and insulin concentrations 
and thus might overlap the classiﬁ cation of the three 
subgroups of type 2 diabetes at diagnosis. However, 
individuals in the fasting subgroup had very diﬀ erent 
trajectories of HOMA-β-cell function than did those in 
the fasting and 2 h subgroup, despite diagnoses based 
on fasting glucose concentrations in both. Whitehall II 
was an occupational cohort, which might not be 
representative for a general European population. 
Nonetheless, no evidence suggests that the trajectories 
in our study would not apply to other populations, 
although the distribution of the diﬀ erent subgroups of 
disease might vary between populations. For example, 
Asian populations have a higher prevalence of diabetes 
based on fasting glucose concentrations and they 
develop type 2 diabetes at lower body-mass indices than 
do white populations.24,29,30 
We were not able to describe sex-speciﬁ c trajectories 
because of the low proportion of women in the study. 
Such ﬁ ndings would have been highly relevant because 
men have higher fasting glucose concentrations  than 
do women.31 Furthermore, with the acceptance of HbA1c 
for use in diagnosis, trajectories of HbA1c concentrations 
in the diﬀ erent subgroups would have been relevant, 
but concentrations were measured only in the last two 
clinical phases. Another limitation is that we had to 
exclude a substantial proportion of incident cases 
diagnosed outside the Whitehall II study because of 
unknown or missing OGTT results, which could limit 
the generalisability of our ﬁ ndings. However, that 
participants with doctor-diagnosed diabetes would 
represent a diﬀ erent disease group from those 
diagnosed on the basis of an OGTT seems unlikely. All 
trajectories for doctor-diagnosed patients were within 
the range of the three diabetes subgroups, supporting 
this suggestion (data not shown). 
In conclusion, type 2 diabetes seems to have diﬀ erent 
natural history and pathogenesis dependent on whether 
it is diagnosed on the basis of increased fasting glucose 
concentrations or increased 2 h glucose concentrations, 
or both. Future studies should establish whether 
glycaemic control, drug needs, and the incidence of 
cardiovascular disease and microvascular complications 
diﬀ er between patients with diﬀ erent subgroups of 
disease. Additionally, a better understanding of the 
genetic and non-genetic causative factors associated with 
diﬀ erent subgroups is needed. Ultimately, assessment of 
the need for stratiﬁ ed prevention and treatment strategies 
is important.
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